Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study

Main Article Content

Jennifer Soung
Lisa Tiu
Karen Veverka
Chih-Ho Hong

Keywords

Abstract

Abstract not available.

 

Disclosures: Study sponspored by LEO Pharma.

 

Copyright 2018 SKIN